1 was identified as a hit in a CCR4 receptor antagonist high throughput screen (HTS) of a sub-set of the AstraZeneca compound bank. As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs.
The chemokine receptor family was originally identified in the 1990s and has since grown in number, complexity and range of biological functions. Originally thought to be simple cell chemo attractants, chemokines have since been shown to exhibit a broader range of functions covering involvement in HIV-1 infection to hematopoiesis and control of cell growth. 1, 2 CCR4 is a G protein-coupled receptor (GPCR) and is activated by the CC chemokines, CCL22 (MDC: macrophagederived chemokine) and CCL17 (TARC: T-cell and activation-related chemokine), 3 leading to cell activation and chemotaxis; it is expressed mainly by Th2 lymphocytes. 4, 5 In keeping with a role for CCR4 in the orchestrated movement of Th2 cells into the allergic lung, both CCL17 and CCL22 have been shown to be elevated in the human lung following allergen challenge. 6 This potential role of CCR4 in driving human allergic lung disease led to many pharmaceutical companies attempting to identify CCR4 receptor antagonists for the treatment of allergic rhinitis and asthma, [7] [8] [9] [10] [11] [12] [13] [14] 15 but as yet no drug has been discovered ( Figure  1 ). 16, 17 In this communication we are disclosing our studies on the optimization of N-(5-bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 to afford two clinical candidates AZD-2098 (47) and AZD-1678 (49). High throughput screening of the AstraZeneca Mixed Chemokine Receptor Antagonist Compound library (~29,000 compounds) using a hCCR4 Fluorescent Microvolume Assay Technology (FMAT) cell binding assay identified compound 1 18, 19 as an inhibitor of labeled CCL22 binding to CCR4 (pIC50 7.2). 20 Subsequently functional antagonism of 1 was shown using an hCCR4 Fluorescence Imaging Plate Reader (FLIPR) intracellular calcium mobilization assay (pIC50 7.0) and a human primary Th2 cell chemotaxis assay (pIC50 6.7). 21 and was shown to be selective for the CCR4 receptor, through screening against an internal panel of chemokine receptors (e.g. CXCR1 & CXCR2, CCR1, CCR2b, CCR5, CCR7 & CCR8; inactive at 10 µM). When screened against a large panel of receptors and enzymes (~120 screens at MDS-Pharma), weak or no activity was observed and therefore 1 was chosen as a starting point for the CCR4 antagonist program. Compound 1 had good solubility (0.34 mg/mL), rat bioavailability (F = 45%) and half-life (T½ ~16 h) when dosed in rat and a similar profile when dose in vivo in mouse. This long half-life was accounted for by a very low clearance (0.1 mL/min/kg), which counteracts the small volume of distribution (Vss 0.1 L/kg).
Compound 1 had very good cross-over with rat and mouse CCR4 receptors (both pIC50 8.3). Subsequently, this species cross-over was shown to be a general feature of the sulfonamide series (see Table 5 ), with the CCR4 receptor from all three species displaying very similar structural activity relationships (SAR). When corrected for plasma protein binding, the predicted rat whole blood potency of 1 was pIC50 5.5 (rat ppb 99.85%) and for mouse 6.8 (mouse ppb 96.7%), giving 1 a suitable profile for use as a target validation tool for in vivo hypothesis testing.
However, the calculated human whole blood potency (WBP) was very poor with predicted activity (pIC50) < 4.2 (calculated from hCCR4 pIC50 7.2 and hPPB >99.9%).
With a candidate drug requiring a WBP pIC50 ~ 6.0, the key issue was to increase WBP by a combination of increasing CCR4 receptor affinity and lowering plasma protein binding, 22 whilst maintaining all the other good features inherent in 1. The high plasma protein binding was attributed to the acidic sulfonamide-NH (measured pKa 4.1) and the lipophilic nature of the molecule (measured logP 4.4).
The structure activity relationship (SAR) generated with respect to modification of the 5-chlorothiophene group is shown in Table 2 . Removal of the 5-chloro substituent 2 gave over a 10-fold drop in affinity, as did the isomeric unsubstituted thiophene 3. Addition of a chlorine to the 4-position of the thienyl group also gave a reduction in affinity (compare 4 with 1) whilst a large substituent (bromine or phenyl) in the 3-position was tolerated (compare 5 and 6 with 1 and 2 respectively). The phenyl analogue 7 was similar to the two unsubstituted thiophenes in potency and introducing chlorine into the 2-, 3-or 4-positions of the phenyl sulfonamide ring (8, 9 and 10) gave an increase in binding relative to 7. The 6-substituted dichlorophenyl sulfonamides (11) (12) (13) (14) (15) (16) (17) had a potency range of almost 3 log units, with the 3,5-dichlorophenylsulfonamide analogue 14 having only weak activity (pIC50 5.3) and the 2,3-dichlorophenylsulfonamide 16 being optimal (pIC50 8.0), almost a log unit more potent than 1. Similar affinity was achieved with 3, 4-dichloro-2-thienyl (compare 18 and 17). A number of other di-substituted phenyl sulfonamides were screened, however no improvement in binding was seen (19-24 compare with 17). Introduction of a nitrogen into the aromatic ring lead to dramatic reduction in potency (25) as did replacement of the aromatic ring with an alkyl group as illustrated with 26.
Whilst an increase in affinity was achieved with compounds 16 and 17, changing the 5-chlorothiophene group for 2, 3-dichlorophenyl did not significantly change the lipophilicity. Consequently, the hPPB figures for these two compounds was also high (>99.9%). The exploration of the 3-position is shown in Table 3 .
with which to attach the 3-substituent to the pyrazine ring. Next, a small number of 3-alkoxy analogues were synthesized (27, 31 and 32). In each case there was a substantial drop in potency relative to the parent methoxy-substituted compound (1 or 17) . However, the 3-allyloxy analogue (33) maintained activity and with the 3-propargyloxy (34) analogue affording a slight increase in activity. Further increases in activity was obtained with 3-OCH2Aryl and 3-OCH2heteroaryl (35, 36, 37 and 38) , where substitution gave substantial increase in activity (pIC50 up to 9.5). Although this SAR demonstrated how to improve on CCR4 affinity, the increase in lipophilicity associated with these changes did not address the plasma protein binding issue with hPPB >99.9% in each case. In contrast to the 3-position, the exploration of the 5-and 6-positions on the pyrazine ring allowed for the discovery of compounds with increased activity combined with lower lipophilicity relative to 17 (Table 4) . A wide variety of substituents were tolerated in the 5-and 6-positions and it was discovered that the percentage plasma protein binding was reduced by lowering the lipophilicity of the compounds, affording plasma protein binding below 99% for compounds of modest lipophilicity (logP < 3.0). For 44, 45, 47, 48 and 49, the calculated WBP (pIC50) of 5.8-6.4 was achieved. These met the candidate drug target profile set of WBP pIC50 ~ 6.0. Of these four compounds, 47 and 49 had the best overall profile for progression (Table 5) . Compounds 47 and 49 demonstrated good selectivity for the CCR4 receptor when screened inhouse against a range of other chemokine receptors (CXCR1 & CXCR2, CCR1, CCR2b, CCR5, CCR7 & CCR8; all inactive at 10 µM) and little or no activity when screened against a large panel of receptors and enzymes (~120 screens at MDS-Pharma). A pharmacokinetic profile commensurate with once-daily oral administration enabled both compounds to progress as candidate drugs. The antagonist potency of 47 and 49 were assessed in a number of cell systems in which a response mediated by the human CCR4 receptor can be evoked by MDC or TARC and quantified using changes in intracellular calcium concentration or chemotaxis. The cell systems used were a cell line (CHO) transfected with the human CCR4 receptor and human CD4+, CD45RA+ Th2 cells in 0.3% HSA. Findings are summarized in Table 6 . The reduced potency in the presence of added protein is consistent with the drop-off predicted from plasma protein binding measurements. Both 47 and 49 demonstrated no agonist activity at concentrations up to 10 M. The anti-inflammatory effects of 47 were investigated in Brown-Norway rats sensitized to ovalbumin. Sensitized rats were dosed orally (bid) with 47 at 0.22, 0.75, 2.2, 3.0, 7.5 and 15 mol/kg 1 hour prior to antigen challenge and every 12 hours thereafter prior to termination 96 hours post challenge. Histopathological examination of the lung tissue showed a marked, dose-dependent reduction in a range of histological correlates with reduced alveolitis and leukocyte trafficking in the microvasculature being the most diagnostic features of efficacy. The changes were first visible at a dose of 0.22 mol/kg and maximal at 7.5 mol/kg. Plasma samples were taken 12 hours after the last dose of compound for measurement of terminal trough concentrations of 47 to demonstrate a strong PKPD correlation (Table 7) . The synthesis of 47 and 49 is shown (Scheme 1). Dibromination of 2-aminopyrazine followed by selective displacement of the bromine in the 3-position with sodium methoxide gave 2-amino-5-bromo-3-methoxypyrazine. The bromine in the 5-position was then removed by hydrogenation and coupling of the 2, 3-dichlorophenylsulphonyl chloride with 2-amino-3-methoxypyrazine afforded 47. A highly-selective 5-position nitration of 47 followed by reduction of the nitro group 52 gave an amino-pyrazine 53 that was diazotized in the presence of hydrofluoric acid to give 49. Scheme 1. i) Br2, dichloromethane, 2,6-lutidine (85-95%) ii) NaOMe (3 eq.), MeOH, reflux (90-95%) iii) H2, Pd/C, ethanol, rt (95%) iv) ArSO2Cl, KOtBu, 0-25°C, THF (80-95%) v) HNO3, AcOH, 70-85 o C (75-82%) vi) H2, Pd/C, AcOH, 60 o C (75-92%) vii) HBF4, CH3CN, 0-5 o C, NaNO2 (40%) or HF / Pyridine / NaNO2 (85%). Range of percentage yields across multiple reactions and scale (~100 mg to >50g).
In summary, a new series of potent and bioavailable amino-pyrazine sulfonamide CCR4 receptor antagonists have been developed from a lead optimization program initiated from a high-throughput screening / synthesis campaign. The initial hit series proved to have reasonable activity but was hindered by having very high human plasma protein binding resulting in a low free fraction of compound. Through chemical modification, both the potency of the series and the free fraction was enhanced to ultimately deliver two clinical candidates. Further studies on these compounds will be reported in due course.
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